Levetiracetam Farmalider (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in neurotransmitter release. This binding modulates vesicle exocytosis, decreasing neuronal hyper‑excitability and stabilizing neuronal firing, thereby reducing the likelihood of seizure initiation and propagation.

The specific dose of levetiracetam is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. The prescriber will tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider, who can weigh the need for seizure control against any possible fetal or infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a distinct mechanism (SV2A binding) and generally fewer drug‑enzyme interactions, which can simplify combination therapy. It is often well‑tolerated, but individual response varies, and selection should be based on seizure type, comorbidities, and patient‑specific factors.

Levetiracetam tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Levetiracetam is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food. Patients should follow the dosing schedule prescribed by their clinician and not alter the dose without medical advice.

Serious adverse reactions, although rare, include severe allergic responses (rash, swelling, breathing difficulty), psychiatric changes such as depression or suicidal thoughts, and hematologic abnormalities like thrombocytopenia. Patients should seek immediate medical attention if they experience any of these symptoms.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment, as dose adjustments may be required, and for those with a history of psychiatric disorders, who should be closely monitored.